

Enterprise Pharmacy and Therapeutics Committee Meeting

Call in number 646-876-9923 Meeting ID 831-139-3271

May 3rd, 2021

5:00PM-7:00PM CST

Pre-register at jplante1@amerihealthcaritasla.com prior to the meeting

<u>Subject</u>	<u>Presenter</u>
1. Call to Order	B. Himmelstein
2. Conflict of Interest Disclosures	S. Cherian
3. BCC Positive Changes, PA Criteria Updates, DUR Reporting	C. Meny
4. Review and approval of February P&T minutes	S. Cherian
5. Old Business	PerformRx
A. Treatment of Hereditary Angioedema (HAE) PA Criteria	p. 84
B. Inhaled Antibiotics and Cystic Fibrosis Agents PA Criteria.....	p. 90
C. Proton Pump Inhibitors (PPIs) PA Criteria.....	p. 92
D. Complement Inhibitors PA Criteria	p. 98
E. SHSC - Safety Edit Exception Criteria	p. 101
6. New Business	PerformRx
A. Xolair for Asthma and Urticaria PA Criteria	p. 104
B. Biologic Agents for Nasal Polyposis PA Criteria	p. 110
C. Self-Administered Disease Modifying Therapies for Multiple Sclerosis...	p. 112
D. Healthcare Professional (HCP) Administered Disease Modifying Therapies for Multiple Sclerosis (MS).....	p. 119
E. Rituximab PA Criteria	p. 126
F. Latuda	p. 133
G. ACNH Continuous Glucose Monitors PA Criteria	p. 135
H. Immune Globulins PA Criteria	p. 137
I. Emergency Use Authorization Drugs/ for COVID-19 PA Criteria	p. 142
J. Gonadotropin Releasing Hormone Agonists (GNRH) PA Criteria	p. 146
K. BCC – Quantity Limit Exception PA Criteria.....	p. 153
L. Hylavite	p. 154
7. Drug Reviews:	PerformRx
A. Therapeutic Class:	
1. Attention Deficit Hyperactivity Disorder with PA Criteria.....	p. 156
2. Phosphate Binders	p. 177
3. Anti-CD19 CAR-T Immunotherapies with PA Criteria.....	p. 182
4. Benzodiazepines for Anxiety	p. 190
5. Contraceptives	p. 196
6. Gaucher’s Disease	p. 203

B. Single Products:	PerformRx
1. Lupkynis	p. 210
2. Oxlumo	p. 221
3. Ridaura.....	p. 227
8. New Products	PerformRx
9. Prior Authorization Criteria Review:	PerformRx
A. Prior Authorization Criteria Annual Review:	
1. Acute Migraine Treatments	p. 251
2. Agents for Thrombocytopenia	p. 257
3. Amyotrophic Lateral Sclerosis (ALS agents)	p. 259
4. Banzel	p. 264
5. Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists for Injection	p. 268
6. Colchicine.....	p. 277
7. Daliresp (ST)	p. 278
8. Erythropoiesis-Stimulating Agents.....	p. 279
9. Injectable Infusible Bone Modifying Agents for Osteoporosis and Paget's Disease.....	p. 290
10. Qalapaquin	p. 302
11. Weight Loss Medications.....	p. 303
12. ACLA - Step Therapy Exception Criteria	p. 305
13. ACLA - Prior Authorization Exception.....	p. 306
14. ACLA - Quantity Limit Exception Criteria.....	p. 307
15. ACLA – Diagnosis Code Requirement	p. 308
16. Long Acting Injectable Antipsychotics	p. 309
17. Multaq.....	p. 313
18. Non-preferred/Prior Authorization Required Medications Criteria. p.	314
19. Palynziq.....	p. 320
20. Pregabalin (Lyrica and Lyrica CR).....	p. 323
21. Primary Hemophagocytic Lymphohistiocytosis (HLH) Agents.....	p. 325
22. Serotonin Receptor Agonists (Triptans).....	p. 327
23. Moxeza.....	p. 329
24. ACDE – Savella.....	p. 330
25. ACDE – Symlin.....	p. 331
26. ACDE – Medications for Management of Obesity	p. 332
B. Prior Authorization Criteria Annual Review without Clinical Changes	
1. Carisoprodol.....	p. 335
2. Diagnosis Code Requirement.....	p. 336
3. Injectable Infusible Bone Modifying Agents for Oncology Indications	p. 338
4. Insulin-Like Growth Factor-1 Receptor (Igf-1r) Antagonists For Thyroid Eye Disease	p. 342
5. itraconazole (Sporanox)	p. 344
6. Ketamine	p. 346
7. Kuvan	p. 348
8. Lidocaine Topical Patches.....	p. 352
9. linezolid (Zyvox).....	p. 353
10. Atovaquone Suspension (Mepron)	p. 354
11. Peanut Allergy Immunotherapy Agents (FDA Approved)	p. 355
12. Potassium Removing Agents	p. 357

13. Oral Atypical Antipsychotics	p. 360
14. Paroxetine ER (ST)	p. 362
15. Vascular Endothelial Growth Factor (VEGF) Inhibitors for Ophthalmic Conditions	p. 363
16. Hemophilia Factor VIII Replacement Products for Hemophilia A .	p. 365
17. ACLA – Oncology Drugs	p. 366
18. ACLA – Specialty Drugs	p. 367
19. ACLA – Safety Edit Exception	p. 368
20. BCC – Siklos	p. 370
21. ACDE – ICS-LABA Step Therapy.....	p. 371
22. ACDE – Incretin Mimetic Drugs Step Therapy	p. 372
23. ACDE – Anti-Depressants for the Pediatric Patient.....	p. 373

C. New Prior Authorization Criteria:

1. Somatostatin Analogues.....	p. 375
2. Off-Label Uses PA Criteria	p. 379
3. Insulin Pumps	p. 381
4. Antisense Oligonucleotides for Duchenne Muscular Dystrophy ...	p. 383

10. Recalls

PerformRx

11. Adjourn

B. Himmelstein

*****NEXT MEETING: July 26th, 2021*****